Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2022-01-20 Board/Management Inform…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia appoints Philipp Mathieu as Acting CEO
Board/Management Information Classification · 98% confidence The document is a press release announcing a significant internal change: the appointment of Philipp Mathieu as Acting CEO. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). The content focuses entirely on personnel changes.
2022-01-20 English
Immunovia utser Philipp Mathieu som tillförordnad vd
Board/Management Information Classification · 99% confidence The document is a press release dated January 20, 2022, announcing the appointment of Philipp Mathieu as the interim CEO and President of Immunovia AB. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The filing code for this category is MANG. The document is short and clearly communicates a management change, not a full financial report or a general regulatory filing.
2022-01-20 Swedish
Immunovia’s CEO to step down during 2022
Board/Management Information Classification · 100% confidence The document is a press release announcing that the company's President and CEO, Patrik Dahlen, intends to step down. This type of announcement, detailing changes in senior management, directly corresponds to the definition of 'Board/Management Information'. The filing type code for this is MANG. The document is short and is a direct announcement, not a comprehensive report.
2021-11-30 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI – SEPTEMBER 2021' (Interim Report January-September 2021). It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary for the specified period. It is clearly a quarterly/interim financial report, not an announcement of a report or a summary factsheet. 9M 2021
2021-11-11 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – SEPTEMBER 2021' and contains comprehensive financial statements, including consolidated income statements, financial position, cash flow, and key indicators for the specified period. It is a full report rather than an announcement, as it contains detailed financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-11 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI - JUNI' (Interim Report January - June) and contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary for the period. It is clearly a quarterly/interim financial report, not an announcement of a report or a summary. H1 2021
2021-08-19 Swedish

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.